NCT02520011 2023-11-15Alvocidib Biomarker-driven Phase 2 AML StudySumitomo Pharma America, Inc.Phase 2 Terminated104 enrolled 12 charts
NCT03593915 2023-11-09A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDSSumitomo Pharma America, Inc.Phase 1/2 Terminated20 enrolled 13 charts
NCT03969420 2023-11-09Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapySumitomo Pharma America, Inc.Phase 2 Terminated11 enrolled 10 charts